source
- STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancerA lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.STAT · 1mo ago↗ source
- STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study findsBy doing hormone therapy upfront in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.STAT · 1mo ago↗ source
- Akeso, Summit drug extends survival in closely watched lung cancer trialThough ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.BioPharma Dive